Stock Movers: Novo Nordisk, Pernod Ricard, Next (Podcast)

The US government negotiated a 71% discount off list price for Novo Nordisk’s Ozempic and Wegovy for Medicare patients, a major pricing concession with potential revenue implications for the company and European pharma peers. JPMorgan’s cautious stance on European consumer staples—citing expected higher unemployment, low consumer confidence and a delivery skew to H2 2026—has weighed on Pernod Ricard. UK retailer Next is exposed to uncertainty around the upcoming budget as companies monitor a possible patchwork of levies, creating further downside risk for UK-focused names.

Analysis

Market structure: The Medicare-negotiated 71% discount on Novo Nordisk’s (NVO) GLP‑1 list price immediately reallocates surplus to payers — losers are NVO and peer pricing power in obesity/diabetes; winners are Medicare, insurers and PBMs (potentially UNH, CVS). Expect volume elasticity to rise (20–50% higher utilization in next 12 months) but average selling price (ASP) shock of ~50–70% for Medicare patients will compress revenue per patient and force global price resets if private payers follow within 6–12 months.

Risk assessment: Tail risks include CMS expanding negotiation to other drug classes, cross-border price harmonization, or supply constraints if demand surges; low-probability but high-impact downside could exceed 40% equity loss for NVO over 6–12 months. Immediate (days) will be volatility spikes and guidance resets; short-term (weeks–months) expect revisions to FY25–26 sales/EBITDA; long-term (quarters–years) structural pricing pressure could reduce pharma sector margins by 200–400bps. Hidden dependencies: formulary placement, rebate mechanics, and PBM economics could invert winners/losers; catalysts are CMS final rule (30–90 days), Q4 earnings, and congressional action.

Trade implications: Direct trade: short NVO exposure and buy payer/MA exposure (e.g., UNH, CVS) — expect payer margin tailwind. Options: favor 3–6 month NVO put‑spreads (buy ATM puts, sell ~25–35% OTM) to cap premium while targeting 20–30% downside; consider long UNH calls to capture 8–15% upside. Sector rotation: trim European consumer staples (e.g., Pernod Ricard) into H1 2026, redeploy into US insurers and select pharma names with non‑GLP‑1 revenue.

Contrarian angles: The market may overstate permanence — 71% applies to Medicare subset; private payers may accept smaller discounts (20–40%), and NVO’s global pricing, pipeline and supply control can recover margins over 12–24 months. Historical parallels (government price caps) show initial equity drawdowns followed by partial recoveries as manufacturers reprice, cut SG&A, or grow volumes; consider a staged long recovery position (12–18 month call spreads) if implied vols overprice permanent damage.

Key Decisions for Investors

• Establish a 2–3% portfolio short exposure to NVO via 3–6 month put‑spread (buy ATM puts, sell 25–35% OTM) targeting 20–30% downside over 3–6 months; stop‑loss if NVO recovers +15% or CMS limits the rule to narrow cohorts.
• Initiate a 2–3% long position in UnitedHealth (UNH) or equivalent MA/insurer exposure, or buy 6‑month UNH calls, targeting 8–15% upside as payers benefit from lower drug ASPs; exit on CMS final rule or after Q4 results (within 60–90 days) if guidance disappoints.
• Trim European consumer staples exposure (e.g., reduce Pernod Ricard weighting by 30–50% vs benchmark) between now and end‑Q1 2026 and reallocate proceeds to US insurer/healthcare payers and non‑GLP‑1 pharma; revisit if unemployment falls below 5% or consumer confidence recovers materially.
• Buy volatility protection on NVO via 3‑month protective put spreads (limit premium outlay) and consider staging a 12–18 month bullish call‑spread (buy 12‑18m OTM calls, sell higher OTM) if implied vol suggests permanent impairment priced >30%.